| 摘要 |
wherein R represents a halogen atom or a C<SUB>1-4 </SUB>alkyl group; R<SUB>1 </SUB>represents a C<SUB>1-4 </SUB>alkyl group; R<SUB>2 </SUB>represents hydrogen or a C<SUB>1-4 </SUB>alkyl group; R<SUB>3 </SUB>represents hydrogen, or a C<SUB>1-4 </SUB>alkyl group; R<SUB>4 </SUB>represents a trifluoromethyl group; R<SUB>5 </SUB>represents hydrogen, a C<SUB>1-4 </SUB>alkyl group or C(O)R<SUB>6</SUB>; R<SUB>6 </SUB>represents C<SUB>1-4 </SUB>alkyl, C<SUB>3-7 </SUB>cycloalkyl, NH(C<SUB>1-4 </SUB>alkyl) or N(C<SUB>1-4</SUB>alkyl)<SUB>2</SUB>; m is zero or an integer from 1 to 3; n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated by tachykinins.
|
